Quotient Sciences is a drug development and manufacturing accelerator providing integrated programs and tailored services across the entire development pathway. Cutting through silos across a range of drug development capabilities, we save precious time and money in getting drugs to patients. Everything we do for our customers is driven by an unswerving belief that ideas need to become solutions, molecules need to become cures, fast. Because humanity needs solutions, fast.
We are a global organization, with operating facilities located in both the UK and US, where we deliver bespoke programs based on the needs of our customers. We possess both formulation development, GMP manufacturing and clinical testing capabilities in both the US and UK for small molecules & peptides and through our recent acquisition of Arcinova, now possess Drug substance and Bioanalysis capabilities as well. We currently have over 1100+ employees globally and are continually growing. We are a dedicated team, passionate about innovating and transforming drug development to help our customers develop new medicines for patients in need.
At Quotient, we possess over 30+ years of expertise in the drug development arena, spanning from candidate selection all the way through commercial product release. We’ve worked on over 3000+ molecules across all stages of development for companies ranging from small biotechs to multi-national large pharma companies, including the top 20 pharma companies around the world. Our scientists have published hundreds of peer reviewed publications & posters that are in the public domain and this continues to be a major focus with our team because we are truly a science-led organization.
We work with our customers in two main capacities, through tailored individual services or through integrated programs at each stage of the development lifecycle- from candidate selection to first-in-human, first-in-human to proof- of -concept and from proof-of concept thru commercial manufacturing. Our unique integrated platform accelerates drug development timelines and in a recent 2020 publication released by the Tufts Center for the Study of Drug Development, revealed that it saved at least 12 months of development time and over $100M in R&D costs, which in turn helped save our customers previous time and costs in getting drugs to patients faster.
New identity depicts extended range of services following acquisitions of Co-Formulate, QS Pharma and SeaView Research